

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/465, 9/50		A2	(11) International Publication Number: WO 00/69440 (43) International Publication Date: 23 November 2000 (23.11.00)
(21) International Application Number: PCT/GB00/01807		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 11 May 2000 (11.05.00)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 9911037.1 13 May 1999 (13.05.99) GB			
(71) Applicant (<i>for all designated States except US</i>): MICAP LIMITED [GB/GB]; Regent House, Heaton Lane, Stockport, Cheshire SK4 1BS (GB).			
(72) Inventor; and			
(75) Inventor/Applicant (<i>for US only</i>): MCNEIGHT, David, Leslie [GB/GB]; Brow Top, Lees Lane, Wilmslow, Cheshire SK9 2LR (GB).			
(74) Agents: MCNEIGHT, David, Leslie et al.; McNeight & Lawrence, Regent House, Heaton Lane, Stockport, Cheshire SK4 1BS (GB).			
(54) Title: NICOTINE DELIVERY SYSTEMS			
(57) Abstract			
There is disclosed a delivery system for nicotine comprising nicotine encapsulated in a microcapsule system which releases the encapsulated nicotine on contact of the microcapsules with a nicotine solvent.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

NICOTINE DELIVERY SYSTEMS

This invention relates to delivery systems for nicotine.

Nicotine is commonly taken in the form of smoking tobacco, in cigarettes, principally, cigars and pipe tobacco. To a lesser extent, tobacco, or a preparation from it, is chewed. More rarely, nowadays, is snuff taken. Smoking is declared to be injurious to health, though nicotine itself, in appropriate quantity, is not harmful in the way smoking is, which is due to components other than the nicotine in cigarette smoke and may even be beneficial - it is reported on numerous occasions as aiding concentration.

Though some question it, nicotine is generally regarded as addictive - certainly, increasing taxes on tobacco, Government health warnings and high profile lawsuits brought against tobacco companies by those made terminally ill, or their bereaved, seem to do little to reduce consumption.

There are several products commercially available to help those wishing to quit smoking. These take the form of tablets, chewing gum and patches, all of which are intended to deliver nicotine without the generation of smoke and its associated carcinogenic or otherwise harmful components.

A problem with formulating such products is that nicotine itself is a quite volatile liquid with a boiling point as low as 123° - 125°C at atmospheric pressure, and this makes it difficult to incorporate in products on account of evaporation losses during formulation and the need to seal the products against evaporation of the nicotine for a reasonable shelf life. At the same time, the nicotine must be readily released on use - in the mouth, in the case of gum or lozenge, or through the skin in the case of a patch.

- 2 -

The manner of injection of nicotine is by dissolving in fatty tissue. Nicotine is not readily absorbed in the gut, and no product is intended to be swallowed.

Patches are, of course, somewhat clinical, and while no doubt quite effective, not aesthetically pleasing. Gum is widely regarded as anti-social, often as much so as smoking - there is a disposal problem involved with gum which by and large its users ignore, which has led to its being outlawed in Singapore, a measure which other countries may well follow. Of all the approaches, the most aesthetically acceptable - lozenges, which leave nothing to dispose of and which can be sucked without the sometimes highly objectionable masticating movements - are perhaps the most difficult to formulate, requiring usually elevated temperature processing, leading to nicotine loss through evaporation and an uncertain final dose in the lozenge, and special protection against evaporation from the finished product, if a reasonable shelf life is to be had.

The present invention provides a nicotine delivery system that avoids problems of the prior art and which can give rise to improved products across the available range, but particularly in regard to the lozenge.

The invention comprises a delivery system for nicotine comprising nicotine encapsulated in a microcapsule system which releases the encapsulated nicotine on contact of the microcapsules with a nicotine solvent.

The nicotine solvent that may be targeted could be the fatty tissue of the buccal cavity.

The microcapsules may comprise yeast cells. The system may comprise a mixture of cells charged with nicotine and diluent, empty cells.

- 3 -

The system may be presented in a solid carrier from the surface of which microcapsules are gradually released for controlled delivery.

The solid carrier may comprise a saliva-soluble or dispersible substance, and may comprise a lozenge, which may be sugar-based. The lozenge may have such a size, solubility and charge of nicotine that it delivers a dosage of nicotine, in use over a time period between 4 and 20 minutes, equivalent to that delivered by a cigarette. The lozenge may be elongate, between 5 and 20 cm in length and snappable as by having preferential snapping positions into a number of portions each capable of comfortable accommodation in the mouth.

The solid carrier may, however, comprise a chewing gum.

The system may comprise a flavouring substance, which may also be encapsulated in a microcapsule system, and may also comprise a vitamin supplement, which also may be encapsulated in a microcapsule system.

The system may be comprised in a patch.

Nicotine delivery systems according to the invention and embodiments of products including the same will now be described with reference to the accompanying drawings, in which:-

Figure 1 is a diagrammatic illustration of a method of preparing microencapsulated nicotine;

Figure 2 is a view of one embodiment of a lozenge product; and

Figure 3 is a view of a second embodiment of a lozenge product.

Figure 1 of the drawings illustrate a method for preparing a delivery system for nicotine comprising nicotine encapsulated in a microcapsule system which releases the encapsulated nicotine on contact of the microcapsules with a nicotine solvent.

Nicotine, in the form of liquid nicotine acid 11, is poured into a mixing vessel 12 with a paddle 13. A measured amount of nicotine is mixed into a given volume of yeast cells 14 in order to give a reasonably concentrated absorption of nicotine into each yeast cell. A suitable mix is 25 g nicotine, 50 g of yeast cells, and 100 g of water. This is stirred for 1-24 hours at about 40°C. Cells are removed by centrifugation and dried. An expected loading is between 25 and 60% by weight of nicotine into the cells, depending on the mix used.

The thus nicotine loaded yeast cells 14 are then poured from the vessel 12, in a second stage of the process, into a larger volume of yeast cells 14 in a second mixing vessel 15, also with a paddle 13, and the mixture stirred.

Thus will a desired concentration of nicotine encapsulated in yeast cells be obtained.

The mixed loaded and diluent yeast cells 14 are then incorporated into products with appropriate quantities of the yeast to give the desired nicotine dose in the product.

Two such products are illustrated in Figures 2 and 3.

- 5 -

Figure 2 illustrates an ingot-shaped candy bar 21 which might be some 9 or 10 cm long so as to fit into a packet such as cigarettes are sold in. The bar 21 has transverse grooves 22 enabling it to be snapped into bite-size pieces.

Figure 3 illustrates a similar product 31, this time shaped more like a cigarette, again with grooves 32 for snapping. The presentations of Figures 2 and 3 were first suggested in GB 2 299 756 A.

These products, which are quite similar to cigarettes and which may be used either as aids to quitting smoking or as cigarette substitutes where smoking is not permitted, will, by virtue of their loaded yeast content, contain an equivalent nicotine dose to that delivered by smoking a cigarette.

Flavourings such for example as mint, Scotch whisky, Cognac or menthol can also be added, again encapsulated in similar fashion to the yeast, as can other beneficial agents such as vitamin supplements.

CLAIMS

1. A delivery system for nicotine comprising nicotine encapsulated in a microcapsule system which releases the encapsulated nicotine on contact of the microcapsules with a nicotine solvent.
2. A nicotine delivery system according to claim 1, in which the nicotine solvent comprises fatty tissue of the buccal cavity.
3. A nicotine delivery system according to claim 1 or claim 2, in which the microcapsules comprise yeast cells.
4. A nicotine delivery system according to claim 3, comprising a mixture of cells charged with nicotine and diluent, empty cells.
5. A nicotine delivery system according to any one of claims 1 to 4, presented in a solid carrier from the surface of which microcapsules are gradually released for controlled delivery.
6. A system according to claim 5, in which the solid carrier comprises a saliva-soluble or dispersible substance.
7. A system according to claim 6, in which the solid carrier comprises a lozenge.
8. A system according to claim 7, in which the lozenge is sugar-based.

- 7 -

9. A system according to claim 7 or claim 8, having such a size, solubility and charge of nicotine that it delivers, in use over a time period between 4 and 20 minutes, an amount of nicotine equivalent to that delivered by a cigarette.
10. A system according to claim 9, in which the lozenge is elongate, between 5 and 20 cm in length and snappable as by having preferential snapping positions into a number of portions each capable of comfortable accommodation in the mouth.
11. A system according to claim 5, in which the solid carrier comprises a chewing gum.
12. A system according to any one of claims 1 to 11, comprising a flavouring substance.
13. A system according to claim 23, in which the flavouring substance is also encapsulated in a microcapsule system.
14. A system according to any one of claims 1 to 13, comprising a vitamin supplement.
15. A system according to claim 14, in which the vitamin is also encapsulated in a microcapsule system.
16. A system according to any one of claims 1 to 4, comprised in a patch.




FIG.1




FIG. 2




FIG. 3

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 November 2000 (23.11.2000)

PCT

(10) International Publication Number
WO 00/69440 A3

(51) International Patent Classification⁷: **A61K 31/465**, 9/50, 9/00

(21) International Application Number: **PCT/GB00/01807**

(22) International Filing Date: 11 May 2000 (11.05.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9911037.1 13 May 1999 (13.05.1999) GB

(71) Applicant (for all designated States except US): MICAP LIMITED [GB/GB]; Regent House, Heaton Lane, Stockport, Cheshire SK4 1BS (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): MCNEIGHT, David, Leslie [GB/GB]; Brow Top, Lees Lane, Wilmslow, Cheshire SK9 2LR (GB).

(74) Agents: MCNEIGHT, David, Leslie et al.; McNeight & Lawrence, Regent House, Heaton Lane, Stockport, Cheshire SK4 1BS (GB).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

(88) Date of publication of the international search report:
5 April 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 00/69440 A3

(54) Title: NICOTINE DELIVERY SYSTEMS

(57) Abstract: There is disclosed a delivery system for nicotine comprising nicotine encapsulated in a microcapsule system which releases the encapsulated nicotine on contact of the microcapsules with a nicotine solvent.

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/GB 00/01807

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/465 A61K9/50 A61K9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 171 906 A (CIBA-GEIGY) 10 September 1986 (1986-09-10) claims 1-3,7,8 page 2, line 69 - line 94 -----	1,2,5,16
A	GB 2 299 756 A (G.F.CLAYTON,UK) 16 October 1996 (1996-10-16) cited in the application claims -----	1-16
A	WO 97 38662 A (FLEMINGTON) 23 October 1997 (1997-10-23) claims 14,15,21,22 example 16 -----	1-16 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

• Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

24 November 2000

Date of mailing of the international search report

30/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scarpioni, U

INTERNATIONAL SEARCH REPORT

Internat'l Application No
PCT/GB 00/01807

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	DE 198 56 432 A (BASF) 15 June 2000 (2000-06-15) claims page 5, line 55 - line 60 page 6, line 48 - line 49 page 9, line 25 - line 37 page 10, line 9 - line 15 -----	1,5-9,16

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern

Application No

PCT/GB 00/01807

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
GB 2171906	A 10-09-1986	US 4680172 A		14-07-1987
		AT 13690 A		15-05-1991
		AT 55386 A		15-05-1991
		AU 5427586 A		16-10-1986
		BE 904342 A		04-09-1986
		CA 1274175 A		18-09-1990
		CH 667993 A		30-11-1988
		DE 3606892 A		18-09-1986
		DK 99086 A		06-09-1986
		FR 2578421 A		12-09-1986
		FR 2602974 A		26-02-1988
		IT 1208735 B		10-07-1989
		JP 8034733 A		06-02-1996
		JP 2043332 C		09-04-1996
		JP 7080769 B		30-08-1995
		JP 61267517 A		27-11-1986
		LU 86324 A		02-09-1986
		NL 8600555 A		01-10-1986
		SE 8600947 A		06-09-1986
		SE 9003219 A		10-04-1992
		US 4765985 A		23-08-1988
		US 4965074 A		23-10-1990
		ZA 8601582 A		29-10-1986
GB 2299756	A 16-10-1996	NONE		
WO 9738662	A 23-10-1997	AU 2190697 A		07-11-1997
		CA 2252038 A		23-10-1997
		EP 0910339 A		28-04-1999
		US 6110486 A		29-08-2000
DE 19856432	A 15-06-2000	WO 0033820 A		15-06-2000